PrintyMed, a Latvian biotech company, has secured approximately €2 million in European Union grant funding to accelerate the development of its biomimetic spider-silk technology for advanced medical applications. The funding comprises €75,000 from the Women TechEU scheme and roughly €700,000 from the European Innovation Council programme, marking a significant milestone for the deeptech startup’s growth trajectory.
The company’s focus centers on developing spider-silk-based membranes designed for organ-on-a-chip systems, a technology increasingly important for drug testing and biomedical research. PrintyMed’s biomimetic approach mimics the properties of natural spider silk to create functional medical devices with enhanced performance characteristics.
Funding and Strategic Direction
The EU grants will support multiple aspects of PrintyMed’s operations and expansion strategy. The capital allocation focuses on advancing research and development of spider-silk-based medical devices, strengthening regulatory and intellectual property expertise, scaling production capabilities, and supporting international partnership and certification efforts. This comprehensive approach positions the company to move from development stage toward commercialization.
The Women TechEU scheme, which provided a portion of the funding, specifically targets female-led technology companies across the European Union. PrintyMed founder and CEO Jekaterina Romanova leads the company, reflecting the growing momentum of women entrepreneurs in Europe’s deeptech sector.
International Expansion Plans
Beyond securing EU funding, PrintyMed is pursuing geographic diversification and partnership opportunities. The company is actively exploring international expansion, with notable focus on developing strategic partnerships in Saudi Arabia. This move suggests confidence in the global market potential for its biomimetic technology and represents a strategic step toward establishing presence in the Middle Eastern market.
The timing of these expansion plans aligns with the company’s enhanced financial position following the EU grants. With stronger resources dedicated to regulatory compliance, intellectual property protection, and production scaling, PrintyMed appears positioned to navigate the complex requirements of entering new international markets.
Broader Ecosystem Context
PrintyMed’s success in accessing EU grant funding reflects the European Commission’s commitment to supporting deeptech and healthtech innovation across member states. The European Innovation Council programme has emerged as a crucial funding mechanism for ambitious startups developing transformative technologies, while initiatives like Women TechEU underscore efforts to address gender disparities in technology entrepreneurship.
Latvia, home to PrintyMed, has increasingly established itself as a participant in Europe’s biotechnology landscape. The country’s startup ecosystem has benefited from EU funding mechanisms and digital infrastructure investments, enabling companies like PrintyMed to develop cutting-edge solutions competing on the global stage.
As organ-on-chip technology continues gaining traction in pharmaceutical and research sectors, startups addressing this space with novel biomimetic approaches may capture significant market opportunities. PrintyMed’s progress demonstrates how European funding schemes can accelerate the commercialization of deeptech solutions while supporting female entrepreneurship and geographic innovation diversity across the continent.